Scarica l'app Stockscreener
1.16
0.87%
0.01
Dopo l'orario di chiusura:
1.14
-0.02
-1.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Immunic Inc Borsa (IMUX) Ultime notizie
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic to offer up to 458.2 million shares of common stock registered for resale by selling stockholdersSEC filing - MarketScreener
Immunic To Offer Up To 458.2 Million Shares Of Common Stock Registered For Resale By Selling StockholdersSEC Filing - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program. - Bitget
Immunic (NASDAQ: IMUX) registers 458.2M resale shares after $200M private placement - Stock Titan
Immunic Regains Nasdaq Compliance, Stabilizing Listing Status - The Globe and Mail
Immunic regains Nasdaq minimum bid price compliance By Investing.com - Investing.com South Africa
Immunic, Inc. (IMUX) stock price, news, quote and history - Yahoo Finance UK
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - Sahm
Immunic, Inc. (IMUX) latest stock news and headlines - sg.finance.yahoo.com
Immunic Regains Nasdaq Compliance as IMUX Stock Maintains Minimum Bid Price Requirement - Minichart
Immunic regains Nasdaq minimum bid price compliance - Investing.com
Immunic Regains Nasdaq Minimum Bid Price Compliance After 20 Consecutive Business Days - TradingView
[8-K] IMMUNIC, INC. Reports Material Event - Stock Titan
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic appoints Jon Congleton to board of directors By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton files initial Form 3 - Stock Titan
Immunic Appoints Biopharma Leader Jon Congleton to Board, Advancing MS Therapy Toward Phase 3 Pivotal Readouts - Minichart
Small cap wrap: BioHarvest Sciences, American Resources, First Phosphate, Immunic... - Proactive financial news
Immunic Adds Veteran Biopharma Leader to Board - tipranks.com
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Immunic Appoints Jon Congleton To Board - citybiz
Immunic appoints Jon Congleton to board of directors - Investing.com
Biopharmaceutical company Immunic, Inc. recently announced the appointment of experienced industry executive Jon Congleton to its board of directors. - Bitget
Veteran biotech leader Jon Congleton joins Immunic (NASDAQ: IMUX) board - Stock Titan
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - ChartMill
Smart Money: Is Immunic Inc stock a good dividend stock2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Growth Review: Is Immunic Inc undervalued by DCF analysisMarket Movement Recap & Fast Gaining Stock Reports - baoquankhu1.vn
Pharma News: Whats next for Immunic Inc stock2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
Immunic Inc Stock Warning Signs - GuruFocus
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - ca.investing.com
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Dr - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - gurufocus.com
Guggenheim Initiates Coverage on Immunic With Buy Rating, $7 Price Target - marketscreener.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - za.investing.com
Immunic stock initiated at Buy by Guggenheim on MS therapy potential - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):